# MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005)

> **NCT00543595** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 154 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Metabolic Syndrome

## Interventions

- **DRUG:** MK0916

## Key facts

- **NCT ID:** NCT00543595
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2005-05
- **Final completion:** 2005-05
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2015-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00543595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00543595, "MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00543595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*